Global Cell Reprogramming Market Size study, By Technology (Sendai Virus-based Reprogramming, mRNA Reprogramming, Episomal Reprogramming, Others), By Application (Research, Therapeutic), By End-User (Research & Academic Institutes, Biotechnology & Pharmaceutical Companies, Hospitals & Clinics), and Regional Forecasts 2022-2028)
Global Cell Reprogramming Market is valued at approximately USD 311.66 million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.15% over the forecast period 2022-2028.
Cell reprogramming techniques, such as a means to repair disease-damaged cells, are used to study stem cells and turn them into remedies for a variety of disorders. These cells are produced from somatic cells, such as blood or skin cells, which have undergone genetic reprogramming to resemble embryonic stem cells in order to produce an unlimited source of a wide range of human cells for therapeutic applications. Global market demand is being accelerated by factors such as growing industry attention on cell reprogramming and growing acceptance of cell reprogramming in cancer research. According to WHO predictions, 57% of people worldwide will have a chronic condition by 2020. Stem cell therapies for a range of illnesses are expected to become more widely used, which will help the business thrive. As a result, key companies are placing a high priority on partnerships and collaborations to drive market expansion, and the covid epidemic is increasing demand for cell reprogramming, which will drive market expansion in the years to come. For instance, in order to increase the focus on developing its core competency in reprogramming somatic cells into iPSCs, Allele Biotechnology & Pharmaceuticals, Inc. and Astellas Pharma, Inc., entered into a licencing agreement through its subsidiary Astellas Institute for Regenerative Medicine (AIRM) in January 2020. Additionally, expanding Cell Reprogramming applications across network segments and rising private cloud demand are predicted to catalyse market demand over the course of the research period. However, ethical concerns related to embryonic stem cells, and limited awareness regarding treatment options restrain market growth over the forecast period of 2022-2028.
The key regions considered for the global Cell Reprogramming market study include Asia Pacific, North America, Europe, Latin America, and the Rest of the World. North America is the leading region across the world in terms of market share owing to the significant growth in iPSC technology and the accessibility of functioning cells for pre-clinical drug testing are likely to be responsible for the high share. The region is growing as a result of high throughput drug toxicity analysis and growing iPSC platform expertise.
Major market players included in this report are:
Allele Biotechnology
ALSTEM
Applied Biological Materials
Axol Bioscience
Creative Bioarray
DefiniGEN
Fujifilm Cellular Dynamics
Lonza
Mogrify
REPROCELL
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Technology:
Sendai Virus-based Reprogramming
mRNA Reprogramming
Episomal Reprogramming
Others
By Application:
Research
Therapeutic
By End-User:
Research & Academic Institutes
Biotechnology & Pharmaceutical Companies
Hospitals & Clinics
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World
Furthermore, years considered for the study are as follows:
Historical year – 2018, 2019, 2020
Base year – 2021
Forecast period – 2022 to 2028
Target Audience of the Global Cell Reprogramming Market in Market Study:
Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors
Companies Mentioned
Allele Biotechnology
ALSTEM
Applied Biological Materials
Axol Bioscience
Creative Bioarray
DefiniGEN
Fujifilm Cellular Dynamics
Lonza
Mogrify
REPROCELL
Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook